Data from a Large Cohort of Patients with mRCC Demonstrate the Feasibility of ctDNA Analysis and High Concordance with Tissue Genomic Analysis
Identification of the most frequently mutated genes in metastatic renal cell carcinoma
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1549 results
Indicators of Outcome Are Identified for Nivolumab Treatment of Patients with Metastatic Clear Cell Renal Cell Carcinoma
Gene signatures and tumour microenvironments were identified that associate with nivolumab outcomes
Early Evaluation of Nutritional Status Is Needed to Provide Nutritional Support and Decrease Risk of Malnutrition, Sarcopenia and Nosocomial Infection in Cancer Patients
Application of the Global Leadership Initiative on Malnutrition criteria
Quantitative Summary of QoL Data Confirms Immune Checkpoint Inhibitor Therapy Is Generally Well-Tolerated
The abundance and heterogeneity of quality of life literature regarding immune checkpoint inhibitors can make patient education difficult
Registry Findings Highlight the Importance of Interdisciplinary Care in Rheumatic irAEs to Improve Patient Outcome Following Immune Checkpoint Inhibitor Therapy
Rheumatic immune-related adverse events resemble classical rheumatic and musculoskeletal diseases with distinct clinical and laboratory characteristics
Pembrolizumab Delivers Clinical Benefit in Selected Histotypes of Rare Sarcoma
The best response in sarcoma patients treated with pembrolizumab was partial response in the AcSé Pembrolizumab study
Promising Preliminary Results Observed with Novel MK-4830 in Patients with Advanced Solid Tumours
MK-4830, an antibody targeting the myeloid-specific ILT4 receptor, shows promise in advanced solid tumours
Nivolumab Shows Promising Activity in Advanced Tumours with Rare Mutations
Data from first clinical study of nivolumab in patients with pathogenic edPOLE mutated MMR-proficient tumours
Pralsetinib Shows Robust Activity in Patients with RET-Altered Medullary Thyroid Cancer
Pralsetinib had activity across all RET alterations and regardless of whether the RET mutation was somatic or germline
Novel Sotorasib Shows Promise in Non-Small Cell Lung Cancer
Sotorasib was active in patients with KRAS p.G12C mutation
Dual p16 and HPV Immunostaining Is Supported for Precise Classification of Oropharyngeal Cancer
Findings from the EPIC-OPC Study
Large Data Analysis Demonstrates Changes in Patient Outcomes and Treatment Strategies Over Time In Patients with Brain Metastasis
During long interval studied lung cancer remained the primary tumour source in patients newly diagnosed with brain metastasis